StockData
Pro Dex Inc logo

Pro Dex Inc (PDEX) company profile

PDEXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 18/306% below fair value
$65.66−1.76 (-2.61%)

Close on Nov 13, 2026Market cap $210.11MP/E 18.1Yield –

About Pro Dex

Surgical & Medical Instruments & Apparatus, SIC 3841

Pro-Dex designs, develops, and manufactures specialized surgical devices, operating as a single business segment. Its core products include autoclavable, electric, and battery-powered multi-function surgical drivers and shavers used in thoracic, orthopedic, and craniomaxillofacial medical procedures. The company also produces rotary air motors, provides non-recurring engineering, consulting, and repair services, and fabricates precision machined components and assemblies for aerospace and defense applications. It primarily serves medical device distributors, original equipment manufacturers, commercial aerospace and defense customers, and the United States government.

The company is headquartered in Irvine, California, and maintains manufacturing and machining operations across facilities located in Irvine, Tustin, and Costa Mesa, California. Pro-Dex employs 206 individuals, five of whom work part-time, with all but four employees working at its facilities within the state of California.

Summary of the business section of Pro Dex's latest annual report, written by StockData.

Company profile

Company

Legal name
Pro Dex Inc
Founded
1994
Headquarters
Irvine, CA
Address
2361 Mcgaw Avenue 92614
Phone
(949) 769-3231
Employees
181, Jun 30, 2026
Industry
Surgical & Medical Instruments & Apparatus
Fiscal year ends
June 30
Auditor
Baker Tilly US, LLP, Irvine, California

Stock & identifiers

Ticker
PDEX
Exchange
Nasdaq
IPO date
Aug 7, 1986
Shares outstanding
3M, Oct 28, 2026
Public float
$67.80M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-3 reverse, Jun 18, 2010
SEC CIK
788920
CUSIP
74265M205
ISIN
US74265M2052
FIGI
BBG000C30865
Share class FIGI
BBG001S6F1W9
LEI
529900EB2AJA079NT411
EIN
84-1261240

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kirk Richard Lee Van JrChief Executive Officer, Director79,703
Alisha CharltonChief Financial Officer22,670
Angelita Rebamontan DomingoDirector18,798
Katrina Marie Kramer PhilpDirector19,796
David HovdaDirector4,300
Raymond E. CabillotDirector272,846
William James Farrell IIIDirector7,100
Nicholas John SwensonDirector1,024,343

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$727.58K$1.12M$353.74K$307–
FY2025$652.95K$1.95M$357.83K$226–
FY2024$441.30K$397.48K$320.50K$103–
FY2023$418.61K$632.14K$297.61K$119–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Richard L. Van Kirk
Director, CEO, President and COO
$350.00K$325.95K–$51.64K$727.58K+11%
Alisha K. Charlton
Chief Financial Officer
$249.84K$60.12K$30.83K$12.95K$353.74K-1%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“At June 30, 2025 we had 181 employees,”

Corporate history

Events identified from SEC filings

See a number that looks wrong?